COMPANY

Encellin

Encellin's ENCRT can provide a living medicine approach for a variety of indications. We build therapies designed to live inside a person’s body. From company website Source · Oct 13, 2026

Keywords: encrt Type 1 Diabetes Type 1 Diabetes Mellitus ENCRT-103-hPI encompasses the ENC-103 device, which will be implanted once loaded with primary islet cargo. ENC-201-CED hPI

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Jan 6, 2027 Trial start Phase 1: ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion. source ↗
May 1, 2024 Trial start Phase 1: Safety of ENC-201-CED ENCRT source ↗

Upcoming milestones

Jul 6, 2028 (ESTIMATED) · Phase 1 · ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion. · NCT07680673

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07680673	ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.	Phase 1	Not yet recruiting	Jan 6, 2027	Jul 6, 2028 (estimated)
NCT06408311	Safety of ENC-201-CED ENCRT	Phase 1	Active, not recruiting	May 1, 2024	Jul 31, 2026 (estimated)